Pieris pharmaceuticals, inc. (PIRS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Jun'14Dec'13
Total revenue

46,279

29,101

25,275

5,831

2,931

5,365

0

12,427

Operating expenses
Research and development

54,996

41,490

22,285

19,699

8,244

5,600

-

9,411

Professional Fees

-

-

-

-

-

-

15

-

General and administrative

18,440

18,442

17,584

8,891

8,368

6,962

0

2,461

Total operating expenses

73,436

59,932

39,869

28,590

16,612

12,563

15

-

Costs and expenses

-

-

-

-

-

-

-

11,873

Loss from operations

-27,157

-30,831

-14,594

-22,759

-13,681

-7,198

-15

553

Interest income

1,714

1,962

152

2

-184

-2,654

-

-

Interest expense

-

-

-

-

-

-

-

493

Other expense, net

-26

1,803

-2,102

120

10

3

-

6

Nonoperating Income (Expense), Total

-

-

-

-

-

-

-

-487

Loss before income taxes

-25,469

-27,066

-16,544

-22,637

-13,854

-9,849

-

66

Benefit for income tax

0

-312

1,103

162

203

-0

-

-

Provision for Income Taxes (Benefit)

-

-

-

-

-

-

0

-

Net Income (Loss) Attributable to Parent

-25,469

-26,754

-17,647

-22,799

-14,058

-9,849

-15

66

Other comprehensive income:
Other comprehensive income/(loss) components:
Foreign currency translation

973

1,196

-2,374

-229

-

-

-

-

Unrealized gain on available-for-sale securities

14

517

-820

0

-

-

-

-

Comprehensive loss

-24,482

-25,041

-20,841

-23,028

-

-

-

-

Reconciliation of Net Loss to net Loss Attributable to Common Stockholders [Abstract]
Net loss attributable to common stockholders

-28,299

-26,754

-

-

-

-

-

-

Earnings Per Share [Abstract]
Weighted Average Number of Shares Outstanding, Basic

-

-

-

-

-

-

5,000

-

Basic and diluted (USD per share)

-0.56

-0.50

-0.40

-0.55

-0.41

-0.71

0.00

0.01

Weighted average number of common shares outstanding
Basic and diluted (shares)

50,625

53,081

43,931

41,713

34,392

13,872

-

11,828

Series C Convertible Preferred Stock
Accretion of Series C convertible preferred stock

2,830

0

-

-

-

-

-

-